Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
N-803 + gemcitabine
- Development stage
- Unknown
- Lead developer
- ImmunityBio
- Modality
- Nucleic Acid-Directed Small Molecules → Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Intravesical, Intravenous, Subcutaneous
01
Overview
N-803 (also known as nogapendekin alfa inbakicept or ANKTIVA) is an interleukin-15 (IL-15) receptor superagonist complex designed to activate and expand natural killer (NK) cells and CD8+ T cells by optimizing in vivo persistence and trans-presentation of IL-15. This immunostimulatory biologic enhances anti-tumor immune responses and has been shown to synergize with other therapies, including monoclonal antibodies and chemotherapeutics. Gemcitabine is a nucleoside analog antimetabolite chemotherapy agent that inhibits DNA synthesis by incorporating into DNA during replication, leading to cell cycle arrest and apoptosis of rapidly dividing tumor cells. The combination of N-803 with gemcitabine is being investigated for its potential to enhance anti-tumor efficacy through both direct cytotoxic effects on cancer cells (gemcitabine) and immune-mediated mechanisms (N-803). Clinical trials are ongoing for various cancers including high-grade ovarian cancer and non-muscle invasive bladder cancer[5][6][7].
- Brand names
- ANKTIVAGemzar
- Other names
- N-803 + gemcitabinenogapendekin alfa inbakiceptgemcitabine
02
Targets
DNA polymerase familyIL2RB (IL-2 receptor beta chain)
Beyond the preview
Go deeper on N-803 + gemcitabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on N-803 + gemcitabine.